Compare DexCom, Inc. (DXCM) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Paychex, Inc. — how do they compare? DexCom, Inc. trades at $77.45 (market cap $28.06B), while Paychex, Inc. trades at $114.27 (market cap $39.12B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays a 4.33% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PAYX | |
|---|---|---|
Market Cap | $28.06B | $39.12B |
Sector | Health | Industrials |
52-Week High | $89.53 | $147.99 |
52-Week Low | $54.84 | $85.57 |
Enterprise Value | $27.03B | $42.60B |
Dividend Yield | — | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Paychex (PAYX) trades at $114.45, up 4.5% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 exceeding expectations, and maintains impressive profitability with 27.03% net income margin and 44.77% ROE. Recent dividend declaration of $1.19 per share and positive business developments including AI expansion support growth outlook.
While valuation metrics appear elevated with P/E of 22.49 and P/S of 6.08, Paychex's strong cash flow generation and market leadership position provide investment appeal. Key risks include competitive pressures and macroeconomic sensitivity to small business hiring trends. Analyst consensus remains cautious with only 16.67% buy ratings, though technical indicators suggest near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
